Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...
Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I would like to hand things over to Mr. Edward Chung. Please go ahead, sir. Good ...
Bio-Rad Laboratories Inc. reports fourth-quarter results Thursday after market close, with investors looking to see whether the life sciences tools maker can sustain momentum from a strong prior ...
Edward Chung: Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends for Bio-Rad Laboratories, Inc. With me on the call today are ...
Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...
Comment anything you want me to go over next! 2nd Channel: Mix & Master - $30 Cover art - $10 paypal.me/iamdices Email: [email protected] Soundcloud: Instagram: Twitter: Facebook: About Dices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results